{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:55:22Z","timestamp":1791248122536,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Azathioprine (aza) therapy is beneficial in the treatment of inflammatory bowel disease, but 10%\u201330% of patients cannot tolerate aza therapy because of adverse drug reactions. Thiopurine S-methyltransferase (TPMT) deficiency predisposes to myelotoxicity, but its association with other side effects is less clear. Inosine triphosphatase (ITPA) mutations are other pharmacogenetic polymorphisms possibly involved in thiopurine metabolism and tolerance.<\/jats:p>\n               <jats:p>Methods: We analyzed data from a 6-month prospective study including 71 patients with Crohn disease undergoing first-time aza treatment with respect to aza intolerance. Patients were genotyped for common TPMT and ITPA mutations and had pretherapy TPMT activity measured.<\/jats:p>\n               <jats:p>Results: Early drop-out (within 2 weeks) from aza therapy was associated with ITPA 94C&amp;gt;A [P = 0.020; odds ratio (OR), 4.6; 95% confidence interval (95% CI), 1.2\u201317.4] and low TPMT activity [&amp;lt;10 nmol\/(mL erythrocytes \u00b7 h); P = 0.007; OR = 5.5; 95% CI, 1.6\u201319.2]. A high-risk group defined by ITPA 94C&amp;gt;A or TPMT &amp;lt;10 nmol\/(mL erythrocytes \u00b7 h) showed significant association with early drop-out (P = 0.001; OR = 11.3; 95% CI, 2.5\u201350.0) and all drop-outs (P = 0.002; OR = 4.8; 95% CI, 1.8\u201313.3). For only drop-outs attributable to aza-related side effects (n = 16), there was a significant association with ITPA 94C&amp;gt;A (P = 0.002; OR = 7.8; 95% CI, 2.1\u201329.1). Time-to-event analysis over the 24-week study period revealed a significant association (P = 0.031) between the time to drop-out and ITPA 94C&amp;gt;A mutant allele carrier status.<\/jats:p>\n               <jats:p>Conclusions: Patients with ITPA 94C&amp;gt;A mutations or low TPMT activity constitute a pharmacogenetic high-risk group for drop-out from aza therapy. ITPA 94C&amp;gt;A appears to be a promising marker indicating predisposition to aza intolerance.<\/jats:p>","DOI":"10.1373\/clinchem.2005.057158","type":"journal-article","created":{"date-parts":[[2005,10,7]],"date-time":"2005-10-07T20:13:48Z","timestamp":1128716028000},"page":"2282-2288","source":"Crossref","is-referenced-by-count":79,"title":["Association of Inosine Triphosphatase 94C&amp;gt;A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study"],"prefix":"10.1093","volume":"51","author":[{"given":"Nicolas","family":"von Ahsen","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University of Go\u0308ttingen, Go\u0308ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W","family":"Armstrong","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University of Go\u0308ttingen, Go\u0308ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Behrens","sequence":"first","affiliation":[{"name":"Clinical Research & Development, Merckle GmbH, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"von Tirpitz","sequence":"first","affiliation":[{"name":"Department of Medicine I, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stallmach","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Saarland University, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Herfarth","sequence":"first","affiliation":[{"name":"Department of Medicine I, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju\u0308rgen","family":"Stein","sequence":"first","affiliation":[{"name":"Department of Medicine I, ZAFES, University of Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bias","sequence":"first","affiliation":[{"name":"Clinical Research & Development, Merckle GmbH, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Adler","sequence":"first","affiliation":[{"name":"Department of Medicine I, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Shipkova","sequence":"first","affiliation":[{"name":"Institute for Clinical Chemistry and Laboratory Medicine, Katharinenhospital, Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oellerich","sequence":"first","affiliation":[{"name":"Department of Clinical Chemistry, University of Go\u0308ttingen, Go\u0308ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Kruis","sequence":"first","affiliation":[{"name":"Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Reinshagen","sequence":"first","affiliation":[{"name":"Department of Medicine I, Klinikum Braunschweig, Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,12,1]]},"reference":[{"key":"2020022800563414000_R1","doi-asserted-by":"crossref","unstructured":"Elion GB. The purine path to chemotherapy. Science1989;244:41-47.","DOI":"10.1126\/science.2649979"},{"key":"2020022800563414000_R2","doi-asserted-by":"crossref","unstructured":"Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med1995;123:132-142.","DOI":"10.7326\/0003-4819-123-2-199507150-00009"},{"key":"2020022800563414000_R3","unstructured":"Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintenance of remission in Crohn\u2019s disease. The Cochrane Database of Systematic Reviews 1998 Issue 4. Art. No.: CD000067. DOI: 10.1002\/14651858.CD000067.."},{"key":"2020022800563414000_R4","unstructured":"Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease. The Cochrane Database of Systematic Reviews 1998, Issue 3 Art. No.: CD000545. DOI:10.1002\/14651858.CD000545.."},{"key":"2020022800563414000_R5","doi-asserted-by":"crossref","unstructured":"Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit2004;26:186-191.","DOI":"10.1097\/00007691-200404000-00018"},{"key":"2020022800563414000_R6","doi-asserted-by":"crossref","unstructured":"Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol1999;39:19-52.","DOI":"10.1146\/annurev.pharmtox.39.1.19"},{"key":"2020022800563414000_R7","doi-asserted-by":"crossref","unstructured":"Armstrong VW, Shipkova M, von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit2004;26:215-219.","DOI":"10.1097\/00007691-200404000-00024"},{"key":"2020022800563414000_R8","doi-asserted-by":"crossref","unstructured":"Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther2004;20:593-599.","DOI":"10.1111\/j.1365-2036.2004.02124.x"},{"key":"2020022800563414000_R9","doi-asserted-by":"crossref","unstructured":"Schu\u0308tz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet1993;341:436.","DOI":"10.1016\/0140-6736(93)93028-Y"},{"key":"2020022800563414000_R10","doi-asserted-by":"crossref","unstructured":"Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med1997;126:608-614.","DOI":"10.7326\/0003-4819-126-8-199704150-00003"},{"key":"2020022800563414000_R11","doi-asserted-by":"crossref","unstructured":"Schu\u0308tz E, von Ahsen N, Oellerich M. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, \u201ctwo-color\/shared\u201d anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem2000;46:1728-1737.","DOI":"10.1093\/clinchem\/46.11.1728"},{"key":"2020022800563414000_R12","doi-asserted-by":"crossref","unstructured":"Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics2004;14:407-417.","DOI":"10.1097\/01.fpc.0000114745.08559.db"},{"key":"2020022800563414000_R13","doi-asserted-by":"crossref","unstructured":"Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn\u2019s disease and severe myelosuppression during azathioprine therapy. Gastroenterology2000;118:1025-1030.","DOI":"10.1016\/S0016-5085(00)70354-4"},{"key":"2020022800563414000_R14","unstructured":"Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev2000;19:293-312."},{"key":"2020022800563414000_R15","doi-asserted-by":"crossref","unstructured":"Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet2002;111:360-367.","DOI":"10.1007\/s00439-002-0798-z"},{"key":"2020022800563414000_R16","doi-asserted-by":"crossref","unstructured":"Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics2004;14:181-187.","DOI":"10.1097\/00008571-200403000-00006"},{"key":"2020022800563414000_R17","doi-asserted-by":"crossref","unstructured":"Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C&gt;A polymorphism and adverse effects from azathioprine. Pharmacogenetics2004;14:779-781.","DOI":"10.1097\/00008571-200411000-00010"},{"key":"2020022800563414000_R18","doi-asserted-by":"crossref","unstructured":"Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF. ITPA genotyping test does not improve detection of Crohn\u2019s disease patients at risk of azathioprine\/6-mercaptopurine induced myelosuppression. Gut2005;54:565.","DOI":"10.1136\/gut.2004.055947"},{"key":"2020022800563414000_R19","doi-asserted-by":"crossref","unstructured":"Shipkova M, Armstrong VW, Wieland E, Oellerich M. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem2003;49:260-268.","DOI":"10.1373\/49.2.260"},{"key":"2020022800563414000_R20","doi-asserted-by":"crossref","unstructured":"Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr1987;423:169-178.","DOI":"10.1016\/0378-4347(87)80340-7"},{"key":"2020022800563414000_R21","doi-asserted-by":"crossref","unstructured":"Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta1978;85:323-333.","DOI":"10.1016\/0009-8981(78)90311-X"},{"key":"2020022800563414000_R22","unstructured":"Schu\u0308tz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc1995;27:1298-1300."},{"key":"2020022800563414000_R23","doi-asserted-by":"crossref","unstructured":"Heller T, Oellerich M, Armstrong VW, von Ahsen N. Rapid detection of ITPA 94C&gt;A and IVS2 + 21A&gt;C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A&gt;C polymorphism on splicing efficiency. Clin Chem2004;50:2182-2184.","DOI":"10.1373\/clinchem.2004.039685"},{"key":"2020022800563414000_R24","doi-asserted-by":"crossref","unstructured":"Barnard GA. Significance tests for 2\u00d72 tables. Biometrika1947;34:123-138.","DOI":"10.1093\/biomet\/34.1-2.123"},{"key":"2020022800563414000_R25","unstructured":"Silva Mato A, Mart\u0131\u0301n Andre\u0301s A. Simplyfying the calculation of the P-value for Barnard\u2019s test and its derivatives. Stat Comput1997;7:143."},{"key":"2020022800563414000_R26","doi-asserted-by":"crossref","unstructured":"Miettinen OS, Nurminen N. Comparative analysis of two rates. Stat Med1985;4:213-226.","DOI":"10.1002\/sim.4780040211"},{"key":"2020022800563414000_R27","doi-asserted-by":"crossref","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc1927;22:209-212.","DOI":"10.1080\/01621459.1927.10502953"},{"key":"2020022800563414000_R28","doi-asserted-by":"crossref","unstructured":"Indjova D, Shipkova M, Atanasova S, Niedmann PD, Armstrong VW, Svinarov D, et al. Determination of thiopurine methyltransferase phenotype in isolated human erythrocytes using a new simple nonradioactive HPLC method. Ther Drug Monit2003;25:637-644.","DOI":"10.1097\/00007691-200310000-00014"},{"key":"2020022800563414000_R29","unstructured":"Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord2003;3 Suppl 1:S30-S38."},{"key":"2020022800563414000_R30","doi-asserted-by":"crossref","unstructured":"Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr Gastroenterol Rep2003;5:506-511.","DOI":"10.1007\/s11894-003-0041-7"},{"key":"2020022800563414000_R31","doi-asserted-by":"crossref","unstructured":"Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?. Ann Clin Biochem2004;41:294-302.","DOI":"10.1258\/0004563041201455"},{"key":"2020022800563414000_R32","doi-asserted-by":"crossref","unstructured":"Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology1998;115:813-821.","DOI":"10.1016\/S0016-5085(98)70251-3"},{"key":"2020022800563414000_R33","doi-asserted-by":"crossref","unstructured":"Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther2002;16:389-398.","DOI":"10.1046\/j.1365-2036.2002.01177.x"},{"key":"2020022800563414000_R34","doi-asserted-by":"crossref","unstructured":"Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther2002;16:1743-1750.","DOI":"10.1046\/j.1365-2036.2002.01353.x"},{"key":"2020022800563414000_R35","doi-asserted-by":"crossref","unstructured":"McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood1995;85:1897-1902.","DOI":"10.1182\/blood.V85.7.1897.bloodjournal8571897"},{"key":"2020022800563414000_R36","doi-asserted-by":"crossref","unstructured":"Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut2001;49:665-670.","DOI":"10.1136\/gut.49.5.665"},{"key":"2020022800563414000_R37","doi-asserted-by":"crossref","unstructured":"Lennard L. Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions. Ther Drug Monit1998;20:527-531.","DOI":"10.1097\/00007691-199810000-00014"},{"key":"2020022800563414000_R38","doi-asserted-by":"crossref","unstructured":"el Azhary RA. Azathioprine: current status and future considerations. Int J Dermatol2003;42:335-341.","DOI":"10.1046\/j.1365-4362.2003.01823.x"},{"key":"2020022800563414000_R39","doi-asserted-by":"crossref","unstructured":"Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E. Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem2004;50:438-441.","DOI":"10.1373\/clinchem.2003.026096"},{"key":"2020022800563414000_R40","doi-asserted-by":"crossref","unstructured":"Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology2000;118:705-713.","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"2020022800563414000_R41","doi-asserted-by":"crossref","unstructured":"Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn\u2019s disease. Aliment Pharmacol Ther2002;16:79-85.","DOI":"10.1046\/j.1365-2036.2002.01156.x"},{"key":"2020022800563414000_R42","doi-asserted-by":"crossref","unstructured":"Xin H, Fischer C, Schwab M, Klotz U. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther2005;21:1105-1109.","DOI":"10.1111\/j.1365-2036.2005.02460.x"},{"key":"2020022800563414000_R43","doi-asserted-by":"crossref","unstructured":"Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther2003;18:395-400.","DOI":"10.1046\/j.1365-2036.2003.01690.x"},{"key":"2020022800563414000_R44","unstructured":"Schwab M, Scha\u0308ffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics2002;12:429-436."},{"key":"2020022800563414000_R45","doi-asserted-by":"crossref","unstructured":"Marinaki AM, Duley JA, Arenas M, Ansari A, Sumi S, Lewis CM, et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids2004;23:1393-1397.","DOI":"10.1081\/NCN-200027639"},{"key":"2020022800563414000_R46","doi-asserted-by":"crossref","unstructured":"Zachara B, Lewandow J. Isolation and identification of inosine triphosphate from human erythrocytes. Biochim Biophys Acta1974;353:253-259.","DOI":"10.1016\/0005-2787(74)90190-7"},{"key":"2020022800563414000_R47","doi-asserted-by":"crossref","unstructured":"Bajaj JS, Saeian K, Varma RR, Franco J, Knox JF, Podoll J, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn\u2019s disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol2005;100:1121-1125.","DOI":"10.1111\/j.1572-0241.2005.41598.x"},{"key":"2020022800563414000_R48","doi-asserted-by":"crossref","unstructured":"Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl2005;11:826-833.","DOI":"10.1002\/lt.20377"},{"key":"2020022800563414000_R49","doi-asserted-by":"crossref","unstructured":"McGovern DP, Travis SP, Duley J, Shobowale-Bakre EM, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology2002;122:838-839.","DOI":"10.1053\/gast.2002.32124"},{"key":"2020022800563414000_R50","doi-asserted-by":"crossref","unstructured":"Dome\u0300nech E, Nos P, Papo M, Lo\u0301pez-San Roma\u0301n A, Garcia-Planella E, Gassull MA. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol2005;40:52-55.","DOI":"10.1080\/00365520410009492"},{"key":"2020022800563414000_R51","doi-asserted-by":"crossref","unstructured":"Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf2004;13:563-567.","DOI":"10.1002\/pds.926"},{"key":"2020022800563414000_R52","doi-asserted-by":"crossref","unstructured":"Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med1989;111:641-649.","DOI":"10.7326\/0003-4819-111-8-641"},{"key":"2020022800563414000_R53","doi-asserted-by":"crossref","unstructured":"Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther2000;14:1561-1565.","DOI":"10.1046\/j.1365-2036.2000.00872.x"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/12\/2282\/32684464\/clinchem2282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/12\/2282\/32684464\/clinchem2282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T01:01:59Z","timestamp":1582851719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/51\/12\/2282\/5629643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2005,12,1]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2005.057158","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,12,1]]},"published":{"date-parts":[[2005,12,1]]}}}